Amarantus Bioscience Holdings Inc (AMBS)

[brharris]

Here is the statement from the conference call transcript:

As far as Amarantus Diagnostics, as we’ve noted we’re preparing for an exit strategy to really unlock the value that we’ve created over the last several years from building this unit. The pipeline we all know in the diagnostics division is headed by LymPro in the diagnostic assay, blood test for Alzheimer’s disease that we’ve developed. We have submitted abstract to the Alzheimer’s Association International Conference for their late-breaking abstract session several weeks ago. Once we received from the clinical study that we’ve just completed LP-002 and we expect that we’ll soon be able to announce whether or not those abstracts have been accepted for public consumption, at meeting. We’re also show sponsor of AAIC. We made that decision obviously after we received the data and we’re very pleased that we’ll be a major part of the AAIC program in July. And we believe it’s going to provide us number of opportunities that we’re already starting to benefit from our business development activities.